Vest Prevention of Early Sudden death Trial (VEST) and VEST Registry
The study design utilizes a single prospective cohort. VEST is a randomized, controlled trial to determine whether a wearable defibrillator vest (LifeVest, ZOLL, Pittsburgh, PA) reduces sudden death and death due to ventricular arrhythmia in the first 90 days following an MI. We hypothesize that a completely non-invasive, wearable defibrillator will decrease sudden death and death due to ventricular arrhythmia by decreasing arrhythmic mortality without an increase in non-arrhythmic mortality.
Participants hospitalized for an acute MI who meet the inclusion and exclusion criteria will be enrolled. They will then be randomized either to vest or no vest in a 2:1 fashion. Both groups will receive optimal post-MI and congestive heart failure (CHF) medical therapy for their condition.
About 1900 participants will be enrolled in VEST from approximately 90 clinical sites. Approximately 75 people will be enrolled at UT Southwestern Medical Center and Parkland Health and amp; Hospital System.
1. Patients identified in the hospital or within 7 days after discharge with a diagnosis of an acute MI (ST elevated MI or Non-ST elevated MI)
2. Left ventricular ejection fraction <=35% determined at the following time point:
a) if no PCI within the first 8 hours following the MI: >=8[Degrees] after MI
b) if acute PCI occurs within 8[Degrees] of MI: >=8[Degrees] after PCI
c) if CABG is planned (before or within 7 days of discharge), wait to enroll and then use
the most recent assessment at least 48[Degrees] post CABG.[Double Quote]
3. Age >18 years